18:27 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Adverum reviewing capsid after discontinuing AAT gene therapy

Adverum Biotechnologies Inc. (NASDAQ:ADVM) will discontinue development of gene therapy ADVM-043 to treat α-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency. The company said that although ADVM-043 was well tolerated among six patients in the open-label, U.S....
14:45 , Nov 2, 2018 |  BC Extra  |  Clinical News

Adverum reviewing capsid after discontinuing AAT gene therapy

Adverum Biotechnologies Inc. (NASDAQ:ADVM) sank $1.21 (27%) to $3.34 on Friday after it said it will discontinue development of gene therapy ADVM-043 to treat α-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency. The company said late Thursday...
22:52 , Jan 5, 2018 |  BC Week In Review  |  Clinical News

Adverum begins Phase I/II of ADVM-043 for AAT deficiency

Adverum Biotechnologies Inc. (NASDAQ:ADVM) began the Phase I/II ADVANCE trial to evaluate ADVM-043 in up to 20 patients with alpha-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency. The study will enroll up to four cohorts, with the...
08:00 , Feb 8, 2016 |  BC Week In Review  |  Company News

Annapurna Therapeutics, Avalanche Biotechnologies deal

Avalanche will acquire Annapurna, gaining four preclinical adeno-associated virus (AAV) gene therapy programs. The programs include ANN-001 , an AAV vector delivering alpha-1 antitrypsin ( AAT ; A1AT ; SERPINA1 ) to treat AAT deficiency;...
02:48 , Feb 2, 2016 |  BC Extra  |  Company News

Avalanche acquires Annapurna

Avalanche Biotechnologies Inc. (NASDAQ:AAVL) will acquire Annapurna Therapeutics S.A.S. (Paris, France), gaining four preclinical gene therapy programs outside of ophthalmology. Annapurna shareholders will receive 17.6 million new Avalanche shares, worth about $105.6 million based on...